There are 2758 resources available
Mutanomes and neoantigens
Presenter: Michal Bassani-Sternberg
Session: Emerging opportunities in cancer immunotherapy
Resources:
Slides
2933 - Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.
Presenter: Karim Fizazi
Session: Proffered paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Proffered paper session - Genitourinary tumours, prostate - Invited Discussant 791O
Presenter: Eleni Efstathiou
Session: Proffered paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
2361 - Carboplatin/pegylated liposomal Doxorubicin/Bevacizumab (CD-BEV) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in patients with recurrent ovarian cancer. A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO Study Group, AGO-Austria, ANZGOG, GINECO, SGCTG).
Presenter: Jacobus Pfisterer
Session: Proffered paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
3404 - Alienor/ENGOT-ov7 randomized trial exploring weekly Paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian Sex Cord tumors (SCT) in relapse
Presenter: Isabelle Ray-Coquard
Session: Proffered paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Optimal multimodal treatment in advanced rectal cancers
Presenter: Maria Antonietta Gambacorta
Session: Standards and advances in rectal cancer
Resources:
Slides
Webcast
Controlling systemic disease: What is needed, and in which sequence?
Presenter: Miriam Koopman
Session: Standards and advances in rectal cancer
Resources:
Slides
Webcast
Who, when and how to test for BRCA mutations
Presenter: Dominique Stoppa-Lyonnet
Session: Clinical implementation of PARP inhibitors
Resources:
Slides
Webcast
What is the true impact of PARP inhibitors in clinical practice?
Presenter: Andrew Tutt
Session: Clinical implementation of PARP inhibitors
Resources:
Slides
Webcast
Managing side effects of PARP inhibitors
Presenter: Shani Paluch-Shimon
Session: Clinical implementation of PARP inhibitors